You are here

Share:

Assay to Screen Anti-metastatic Drugs

Summary
The National Cancer Institute seeks licensees for a model used to study molecular mechanisms and/or signaling pathways involved in tumorigenesis, angiogenesis and metastasis of breast cancer and its response to therapy.
NIH Reference Number
E-088-2013
Product Type
Keywords
  • cell line
  • tumorigenesis
  • angiogenesis
  • metastasis
  • triple negative breast cancer
Collaboration Opportunity
This invention is available for licensing.
Contact
Description of Technology

Scientists at the NCI developed a research tool, a murine cell line model (JygMC(A)) with a reporter construct, of spontaneous metastatic mammary carcinoma that resembles the human breast cancer metastatic process in a triple negative mammary tumor. The assay is useful for screening compounds that specifically inhibit pathways involved in mammary carcinoma and can improve clinical management of of triple negative breast cancer that are greatly refractory to conventional chemo and radiotherapy. The key feature of the cell line is that when introduced orthotopically into the mammary gland of immunocompromised mice it produces murine mammary tumors that rapidly metastasize to distant sites, such as lungs, lymph nodes, liver and kidneys. This allows for precise tracking of tumor growth and metastasis.

Potential Commercial Applications
  • Laboratory tool to investigate molecular mechanisms and/or signaling pathways involved in tumorigenesis, angiogenesis and  metastasis of breast cancer and its response to therapy  (in vivo and in vitro).
  • Research tool for high through-put screening of libraries for compounds that specifically inhibit mechanisms and/or signaling pathways involved in metastatic triple negative breast cancer.
  • Research tool to optimize therapeutic regimens.
Competitive Advantages
  • Dual report construct: enhanced green fluorescent protein (eGFP) or a fusion of firefly luciferase and eGFP (ffLuc2-eFGP) and mouse Cripto-1 promoter sequence cloned into a vector for reporter assays and/or visualization of  molecular mechanisms involved in tumorigenesis of metastatic breast cancer cells.
Inventor(s)

Nadia P. Castro, David S. Salomon (NCI), Frank F. Cuttitta

Development Stage
Publications

Nadia P. Castro "Role of the Notch signaling in the metastasis of a murine breast cancer model." Abstract presented at the Mammary Gland Biology Gordon Research Conference, Lucca (Barga) Italy, June 10-15, 2012.

Nadia P. Castro "Notch pathway in an experimental model of breast cancer metastasis." Abstract presented at the Sixth AACR Special Conference on Advances in Breast Cancer Research, San Francisco, California, October 12-15, 2011.

Patent Status
  • Research Material: NIH will not pursue patent prosecution for this technology
Therapeutic Area
Updated
Thursday, June 7, 2018